Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

The PERLA trial showed consistent OS benefits across various PD-L1 tumor proportion scores, favoring Jemperli over Keytruda.

Padcev may be given alone or in combination with pembrolizumab (Keytruda). In Padcev clinical trials, the more common side effects differed depending on the treatment received. These are just a ...

Vaccines are the original immunotherapy, in the view of Ryan Sullivan, a cancer immunotherapy researcher and oncologist at ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

Merck has said it will abandon the KEYNOTE-991 study of PD-1 inhibitor Keytruda (pembrolizumab ... but was associated with considerable side effects that forced a change in dosing regimen.

Notably, 20.8% of patients who received ivonescimab experienced serious treatment-related side effects vs. 16.1% of Keytruda ...

Keytruda is used mainly with four cycles of ... That should stave off some of chemo’s side effects, but as the checkpoint inhibitors – and particularly Yervoy – have their own tolerability ...

Lastly, the growing success of Keytruda has increased the firm's dependence on the drug for growth, which could become problematic if any side effects show up or new therapies emerge quickly in ...

Medically reviewed by Doru Paul, MDTriple-negative breast cancer (TNBC) is difficult to treat due to its aggressive nature.

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...